| Therapeutic drug monitoring of ziprasidone in a clinical treatment setting. | |
| | |
MedLine Citation:
|
PMID: 18824954 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
There is limited information on the pharmacokinetics ofziprasidone (ZIP) in naturalistic clinical settings. The objective of this study was to investigate the concentrations of ZIP and its active metabolite S-methyl-dihydroziprasidone (SMDZ), and the dose-normalized concentrations, using routine therapeutic drug monitoring (TDM) data. A high-performance liquid chromatographic method for determining serum concentrations of these substances for routine clinical use was established at the TDM Laboratory in Linköping, Sweden. This analytical service was available to all physicians in Sweden. Between January 2001 and December 2004, 545 analyses, representing samples from 370 patients, were performed. The median daily ZIP dose was 120 mg (range 20 -320 mg). In all, 121 steady-state trough specimens with essential clinical information were included in the pharmacokinetic evaluation. The median (25th to 75th percentile) serum concentration of ZIP was 125 nmol/L (82-188 nmol/L). The SMDZ:ZIP ratio decreased with increasing serum concentration of ZIP. The median (25th to 75th percentile) dose-normalized concentrations (nmol L(-1) mg(-1) d(-1) forZIPand SMDZ were 1.13 (0.74-1.77) and 0.62 (0.45-0.86), respectively,with SMDZ:ZIP ratio of 0.57 (0.42-0.79). The overall coefficients of variation for dose-normalized serum concentrations of ZIP, SMDZ, andSMDZ:ZIP ratio were 62%, 56%, and 57%, respectively (n = 121). Smoking women had lower normalized ZIP concentrations than nonsmoking women. Twenty-eight patients with repeated eligible TDM analyses were studied for intraindividual variance over time. In summary, great interindividual and intraindividual differences in ZIPconcentrations were observed. TDM of ZIP maybe used for individual dose adjustments and monitoring medication adherence. |
| | |
Authors:
|
Maria D Chermá; Margareta Reis; Staffan Hägg; Johan Ahlner; Finn Bengtsson |
Related Documents
:
|
12222544 - Differences in antimicrobial drug exposure in patients with various degrees of renal fu... 21805354 - Comparative in vitro activities of fluconazole, voriconazole, and mxp-4509 against roma... 17317584 - Pharmacokinetic disposition and clinical outcomes in infants and children receiving int... 9208354 - Time of peak drug concentration after a single dose and a dose at steady state. 1385074 - Investigations of the acute toxic, cytogenetic, and embryotoxic activity of buminafos. 9685064 - Methodology for determining action levels for clean-up contaminated urban and agricultu... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Therapeutic drug monitoring Volume: 30 ISSN: 1536-3694 ISO Abbreviation: Ther Drug Monit Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2008-12-05 Completed Date: 2009-03-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7909660 Medline TA: Ther Drug Monit Country: United States |
Other Details:
|
Languages: eng Pagination: 682-8 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, Faculty of Health Sciences, Linkoping University Hospital, Sweden. maria.dolores.cherma.yeste@lio.se |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Age Distribution Aged Aged, 80 and over Antipsychotic Agents / adverse effects, blood, metabolism, pharmacokinetics* Child Drug Interactions Drug Monitoring* Female Humans Male Middle Aged Piperazines / adverse effects, blood, metabolism, pharmacokinetics* Product Surveillance, Postmarketing Sex Characteristics Smoking Thiazoles / adverse effects, blood, metabolism, pharmacokinetics* |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/Piperazines; 0/S-methyl-dihydroziprasidone; 0/Thiazoles; 146939-27-7/ziprasidone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Differential effects of factor IIa inhibitors on the endogenous thrombin potential.
Next Document: Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxybutyric ac...